Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard
Aim. A meta-analysis of 8 controlled studies (n=771, age 53.6±6.2 years) of tie use of tie Chondroguard (100 mg i.m. first 3 injections, from tie 4th injection - 200 mg i.m., EOD, course 20-30 injections) in the complex therapy of osteoarthritis (OA).Materials and Methods. Tie meta-analysis accordin...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2021-02-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/453 |
| _version_ | 1797878872709005312 |
|---|---|
| author | I. Yu. Torshin A. M. Lila A. V. Naumov A. Yu. Kochish L. I. Alekseeva E. A. Taskina I. V. Sarvilina A. N. Galustyan A. N. Gromov A. K. Khadzhidis L. V. Vasilieva E. F. Yevstratova M. I. Udovika O. A. Gromova |
| author_facet | I. Yu. Torshin A. M. Lila A. V. Naumov A. Yu. Kochish L. I. Alekseeva E. A. Taskina I. V. Sarvilina A. N. Galustyan A. N. Gromov A. K. Khadzhidis L. V. Vasilieva E. F. Yevstratova M. I. Udovika O. A. Gromova |
| author_sort | I. Yu. Torshin |
| collection | DOAJ |
| description | Aim. A meta-analysis of 8 controlled studies (n=771, age 53.6±6.2 years) of tie use of tie Chondroguard (100 mg i.m. first 3 injections, from tie 4th injection - 200 mg i.m., EOD, course 20-30 injections) in the complex therapy of osteoarthritis (OA).Materials and Methods. Tie meta-analysis according to tie fixed-effects model included all published clinical studies on tie efficacy and safety of the CG drug in OA). The effectiveness of therapy was assessed using the VAS, Lequesne, WOMAC scales/indices. For each study, information was collected on 23 features. Data analysis was carried out using the MEDSTUDY and "R" software packages.Results. Meta-analysis confirmed significant associations between the use of Chondroguard (CG. and pain reduction assessed by the visual analog scale (V)S. - CG: a decrease in pain intensity by -28.3 points, control: -11.6; p=0.042. There was a significant reduction in pain according to VAS at night (CG: -20.1; control: -9.9; p=0.05018., while sitting or lying down (CG: -15.5; control: -7.6; p=0.01656., when walking (CG: -28.2; control: -17.0; p=0.04957). The use of CG led to a significant decrease in the scores of the Lequesne index (CG: -4.3; control: -1.4; p=0.0349., and of the WOMAC index (CG: -338.4; control: -219.8; p=0.004., including WOMAC "function" (CG: -247.8; control: -96; p=0.0027., and WOMAC "stiffness" (CG: -25.4; control: -11.2; p=0.0462.. The incidence of side effects did not differ significantly from the control.Conclusion. Chondroguard is an effective treatment for osteoarthritis and has a good safety profile. |
| first_indexed | 2024-04-10T02:39:56Z |
| format | Article |
| id | doaj.art-50ed813ea5424caba4b879cc395f0cd1 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:39:56Z |
| publishDate | 2021-02-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-50ed813ea5424caba4b879cc395f0cd12023-03-13T07:48:17ZrusIRBIS LLCФармакоэкономика2070-49092070-49332021-02-0113438839910.17749/2070-4909/farmakoekonomika.2020.066322Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with ChondroguardI. Yu. Torshin0A. M. Lila1A. V. Naumov2A. Yu. Kochish3L. I. Alekseeva4E. A. Taskina5I. V. Sarvilina6A. N. Galustyan7A. N. Gromov8A. K. Khadzhidis9L. V. Vasilieva10E. F. Yevstratova11M. I. Udovika12O. A. Gromova13Federal Research Center Computer Sciences and Control, Russian Academy of Sciences; Moscow State UniversityV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian FederationPirogov Russian National Research Medical UniversityNational Medical Research Center of Traumatology and Orthopaedics named by R.R.VredenV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian FederationV.A. Nasonova Research Institute of RheumatologyMedical Center Novomeditsina, LLCSt. Petersburg State Pediatric Medical UniversityFederal Research Center Computer Sciences and Control, Russian Academy of Sciences; Moscow State UniversitySt. Petersburg State Pediatric Medical UniversityState budgetary educational institution of higher professional education "Voronezh State Medical University named after N.N. BurdenkoState budgetary educational institution of higher professional education "Voronezh State Medical University named after N.N. BurdenkoFederal state institution of public health services Medical-sanitary part of the Ministry of Internal Affairs of the Russian Federation the Ulyanovsk regionFederal Research Center Computer Sciences and Control, Russian Academy of Sciences; Moscow State UniversityAim. A meta-analysis of 8 controlled studies (n=771, age 53.6±6.2 years) of tie use of tie Chondroguard (100 mg i.m. first 3 injections, from tie 4th injection - 200 mg i.m., EOD, course 20-30 injections) in the complex therapy of osteoarthritis (OA).Materials and Methods. Tie meta-analysis according to tie fixed-effects model included all published clinical studies on tie efficacy and safety of the CG drug in OA). The effectiveness of therapy was assessed using the VAS, Lequesne, WOMAC scales/indices. For each study, information was collected on 23 features. Data analysis was carried out using the MEDSTUDY and "R" software packages.Results. Meta-analysis confirmed significant associations between the use of Chondroguard (CG. and pain reduction assessed by the visual analog scale (V)S. - CG: a decrease in pain intensity by -28.3 points, control: -11.6; p=0.042. There was a significant reduction in pain according to VAS at night (CG: -20.1; control: -9.9; p=0.05018., while sitting or lying down (CG: -15.5; control: -7.6; p=0.01656., when walking (CG: -28.2; control: -17.0; p=0.04957). The use of CG led to a significant decrease in the scores of the Lequesne index (CG: -4.3; control: -1.4; p=0.0349., and of the WOMAC index (CG: -338.4; control: -219.8; p=0.004., including WOMAC "function" (CG: -247.8; control: -96; p=0.0027., and WOMAC "stiffness" (CG: -25.4; control: -11.2; p=0.0462.. The incidence of side effects did not differ significantly from the control.Conclusion. Chondroguard is an effective treatment for osteoarthritis and has a good safety profile.https://www.pharmacoeconomics.ru/jour/article/view/453osteoarthritisevidence-based medicinedata analysischondroitin sulfatechondroguard |
| spellingShingle | I. Yu. Torshin A. M. Lila A. V. Naumov A. Yu. Kochish L. I. Alekseeva E. A. Taskina I. V. Sarvilina A. N. Galustyan A. N. Gromov A. K. Khadzhidis L. V. Vasilieva E. F. Yevstratova M. I. Udovika O. A. Gromova Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard Фармакоэкономика osteoarthritis evidence-based medicine data analysis chondroitin sulfate chondroguard |
| title | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard |
| title_full | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard |
| title_fullStr | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard |
| title_full_unstemmed | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard |
| title_short | Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard |
| title_sort | meta analysis of clinical trials of osteoarthritis treatment effectiveness with chondroguard |
| topic | osteoarthritis evidence-based medicine data analysis chondroitin sulfate chondroguard |
| url | https://www.pharmacoeconomics.ru/jour/article/view/453 |
| work_keys_str_mv | AT iyutorshin metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT amlila metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT avnaumov metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT ayukochish metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT lialekseeva metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT eataskina metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT ivsarvilina metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT angalustyan metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT angromov metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT akkhadzhidis metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT lvvasilieva metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT efyevstratova metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT miudovika metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard AT oagromova metaanalysisofclinicaltrialsofosteoarthritistreatmenteffectivenesswithchondroguard |